Eledon Pharmaceuticals Inc (ELDN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $178.63M
Last updated: Nov 17, 2026 at 4:15 PM ET
Eledon Pharmaceuticals Inc (ELDN) Statistics
Eledon Pharmaceuticals (ELDN) has a market cap of $178.63M and an enterprise value of $171.75M. Its share count is up 48.69% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 3.85% below the market cap, as cash exceeds debt.
| Market Cap | $178.63M |
|---|---|
| Enterprise Value | $171.75M |
| Latest price (Nov 17, 2026) | $1.98 |
Key Dates
The next earnings report is expected on Mar 17, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 17, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 12, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is up 12.50% over 52 weeks and trades 21.43% below its 50-day average.
| Beta (1Y) | 1.84 |
|---|---|
| 52-Week Change | +12.50% |
| 1-Month Change | -8.33% |
| 3-Month Change | -44.23% |
| 6-Month Change | -44.69% |
| 5-Year Change | -44.60% |
| 10-Year Change | -98.44% |
| Total Return (1Y) | +12.50% |
| Total Return (3Y CAGR) | +15.95% |
| Total Return (5Y CAGR) | -19.07% |
| Return vs SPY (1Y) | +17.01% |
| Max Drawdown (1Y) | -53.21% |
| Max Drawdown (3Y) | -73.77% |
| Sharpe Ratio (1Y) | 0.37 |
| Correlation with SPY (1Y) | 0.37 |
| 50-Day Average | $2.52 |
| 200-Day Average | $3.12 |
| 52-Week Range | $1.35 to $4.49 |
| RSI (14 Days) | 36.2 |
| Average Volume (20 Days) | 965.55K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 6.30x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 6.30x |
|---|---|
| Quick Ratio | 6.30x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -276.12% and return on assets is -79.74% over the last 12 months.
| Return on Equity (ROE) | -276.12% |
|---|---|
| Return on Assets (ROA) | -79.74% |
| Return on Capital Employed (ROCE) | -89.53% |
| ROA (5Y Average) | -58.65% |
| ROIC (5Y Average) | -56.22% |
Scores
ELDN has a Piotroski F-Score of 0 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 0 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Operating Income | -$87.21M |
| Pretax Income | -$85.00M |
| Net Income | -$85.03M |
| EBITDA | -$85.00M |
| EBIT | -$85.00M |
| Reported EPS (TTM) | -$0.80 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 28.88% of the $106.64M in total assets.
| Cash and Equivalents | $6.88M |
|---|---|
| Total Debt | $0 |
| Net Cash | $6.88M |
| Net Cash Per Share | $0.06 |
| Working Capital | $62.01M |
| Shareholder Equity | $30.80M |
| Book Value Per Share | $0.27 |
| Total Assets | $106.64M |
| Total Liabilities | $36.83M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$78.36M |
|---|---|
| FCF Per Share | -$0.96 |
Trailing 12 months through Sep 30, 2026.
Dividends and Yields
ELDN does not pay a dividend.
| Buyback Yield | -23.59% |
|---|---|
| Shareholder Yield | -23.59% |
Stock Splits
The last split was a 1-for-18 reverse split on Oct 5, 2020.
| Last Split Date | Oct 5, 2020 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:18 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About ELDN
What is ELDN's market cap?
Eledon Pharmaceuticals has a market cap of $178.63M. Its enterprise value, which adds debt and subtracts cash, is $171.75M.
How many shares of ELDN are outstanding?
Eledon Pharmaceuticals has 114.72M shares outstanding. The count is up 48.69% from a year earlier.
Does ELDN pay a dividend?
No. Eledon Pharmaceuticals does not pay a dividend.
How much debt does ELDN have?
Eledon Pharmaceuticals has $0 of total debt and $6.88M of cash and equivalents, a net cash position of $6.88M.
ELDN pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors